Loading
A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC is a phase 2 interventional study registered as NCT05044897 by Sichuan Baili Pharmaceutical Co., Ltd., with 11 participants enrolled, started 2021-10-20 and due to reach its primary completion in 2025-12. Interventions recorded: SI-B001. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.